ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0754

Persistent but Disturbed Germinal Center Reaction Among 3rd SARS-CoV-2 Vaccination After Rituximab Exposure
Abstract Number: 0755

Immune Responses and Disease Marker Changes Following SARS-CoV-2 mRNA Vaccination in a Cohort of Rheumatic Disease Patients
Abstract Number: 0756

Rheumatic Toxicities of Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and the Effect of Pre-existing Autoimmune and Non-immune Mediated Rheumatic Conditions
Abstract Number: 0757

Safety and Effectiveness of Immune Checkpoint Inhibitors Combination versus Single Agent Therapy in Patients with Pre-existing Autoimmune Diseases
Abstract Number: 0758

Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE)-like Syndrome After Immune Checkpoint Inhibition: A CanRIO Study
Abstract Number: 0759

Immunogenicity of COVID-19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Diseases (AIIRD) on Immunomodulatory Therapies (IMT): An Updated Cohort Study
Abstract Number: 0760

Prevalence of Autoimmune Conditions in Metastatic Melanoma Patients Starting Checkpoint Inhibitors
Abstract Number: 0761

Identification of Outcome Domains in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis and Polymyalgia Rheumatica: A Scoping Review by the OMERACT IrAE Working Group
Abstract Number: 0762

Rituximab-treated Rheumatic Patients: B-cell Levels Predict Sero-conversion After COVID-19 Boost or Re-vaccination in Initial Vaccine Non-responders
Abstract Number: 0763

Immunogenicity Analysis from the VOLTAIRE Trials in Patients with Rheumatoid Arthritis, Crohn’s Disease, and Chronic Plaque Psoriasis
Abstract Number: 0764

No Impact of Prior DMARD Exposures on Mortality in US Veterans with Cancer Treated with Immune Checkpoint Inhibitors
Abstract Number: 0765

The Impact of Immunomodulating Treatment on the Immunogenicity of COVID-19 Vaccines in Patients with Immune-mediated Inflammatory Rheumatic Diseases Compared to Healthy Controls. a Swedish Nationwide Study (COVID19-REUMA)
Abstract Number: 0766

CCP+ Immune Checkpoint Inhibitor Arthritis Patients Have Less ACPA Epitope Expansion Than CCP+ Rheumatoid Arthritis Patients
Abstract Number: 0767

Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) – A Retrospective Chart Review Study of Adults with Inflammatory Arthritis Associated with Cancer Immunotherapies
Abstract Number: 0768

Reevaluating Clinical Outcomes of Patients on Combination Biologics

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].